Sign inJoin waitlistJoin the waitlist

Avanthi Shah

Assistant Professor · University of Texas Southwestern Medical Center

Credentials: · · ·

History

University of Texas Southwestern Medical Center
Present
Children's Health Andrews Institute
Present

Pediatric Hematology Oncology
Standford University School of Medicine
2015–2016
Hematology and Medical Oncology
Stanford University School of Medicine
2013–2016
Univ of Texas Southwestern Med Sch at Dallas
2005–2009
Pediatrics
University of Texas Southwestern Medical Center
2006–2009

Research

Genome-Informed Targeted Therapy for Osteosarcoma
Cancer Discovery · 2019 · 368 citations
A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas
Molecular Cancer Therapeutics · 2021 · First of 23 authors · 39 citations
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Clinical Cancer Research · 2024 · 34 citations

Alejandro Sweet-Cordero
9 papers
Florette Hazard
5 papers
Aviv Spillinger
4 papers · 2 as a resident
Soo-Jin Cho
4 papers
David Mohler
3 papers
Raffi Avedian
3 papers
SS
Sheri Spunt
3 papers
Arun Rangaswami
2 papers
Brian Turpin
2 papers
Douglas Hawkins
2 papers
Heng-Yi Liu
2 papers · 1 as a resident
Krystal Straessler
2 papers · 2 as a fellow

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
Site PI · Recruiting · Phase 1, Phase 2
Nationwide Children's Hospital
2022–2027